Hints and tips:
Related Special Reports
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The Independent Sage group of scientists issued an “emergency statement” urging the government to rule out immediately plans to lift the last restrictions on June 21....
...Dr Robert Challen of the University of Exeter, whose modelling of the variant from India was presented to the government’s scientific advisory group, Sage, said it was hard to reach a definitive conclusion...
...“Africa is a key market for Sputnik V,” said the Russian Direct Investment Fund, a Kremlin-run wealth fund overseeing Sputnik V’s foreign sales....
...“I feel very strongly that we should get as many shots in arms as possible, right away,” Mr Gottlieb told USA Today last week. “The reality is that one dose is partially protective....
...BioNTech said its trials, run with US pharmaceutical group Pfizer, were largely based on two doses administered roughly three weeks apart and that this remained the recommended advice....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...If there is a sense from this earnings season that confidence in a V-shaped recovery for profits is misplaced, then the impact will probably be hardest on companies with weak balance sheets, and on those...
...JP Morgan Cazenove’s selling Sage on SME spending worries: Sage published its Q3 IMS statement last week, reporting organic total revenue growth of 1.1% (and 4.1% YTD)....
...Beyond these three biotechs, Crispr could end up transforming the entire pharmaceutical industry....
...Inc — in other words offering a dire signal on the outlook”....
...And although China’s pharmaceutical industry has matured a great deal in recent years, it is still far better at incremental innovation than breakthroughs....
...Their concentrated ownership of industries such as airlines and pharmaceuticals may push up travel and drug prices, some academics argue....
...In particular, WBA pointed to a 2.3 per cent year-on-year rise in sales at its main Retail Pharmacy USA division, with a rise in pharmacy sales offsetting declining retail sales....
...DD’s Indap v NYU’s Damodaran: Is stock compensation good or bad?...
...(v) Restructuring continues. Of course it does. But what about that Tesla, eh?...
...In September last year, Novartis said it would sell parts of the Sandoz US business to Aurobindo Pharma USA to focus on “higher growth areas”....
...Campari will be hard hit by COVID-19 due to high On Trade exposure, especially in core markets of Italy and the USA....
...“A baby, gasping on an abortion clinic table, should not be left to die,” Republican Ben Sasse, the Nebraska senator wrote in an op-ed for USA Today....
...On Thursday, Novartis said it would sell portions of the Sandoz US portfolio to Aurobindo Pharma USA in order to focus on “higher growth areas”....
...She worked as a janitorial supervisor at C&W client Lonza, a Swiss pharmaceuticals group, which has a production facility in Portsmouth, New Hampshire....
...“Anyone with the appetite and dollars to buy can, whether it’s a Patrick Soon-Shiong [the pharmaceuticals billionaire who owns the LA Times] or an Alden.”...
...The 1984 case, formally known as “Chevron USA Inc v Natural Resources Defense Council Inc” formalised the legal doctrine that requires judges to defer to administrative agencies’ interpretation of federal...
...This “abstinence v medication” debate has raged in the US since 1914, when the country’s first major narcotics laws were passed, according to Nancy Campbell, a historian at Rensselaer Polytechnic in New...
International Edition